Phase I trial shows that a drug that inhibits the Notch signalling process is active in a range of advanced cancers

A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumors. Importantly, it has been able to do this in rare cancers that are less well-studied such as adenoid cystic carcinoma.